Navigation Links
GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
Date:8/30/2010

LONDON, RESEARCH TRIANGLE PARK, N.C., and ALISO VIEJO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine* to 30 November 2010.  The original goal date was 30 August 2010.

The FDA has not yet completed the review of the New Drug Application (NDA) for ezogabine due to the recent submission of a formal REMS (Risk Evaluation and Mitigation Strategy) for ezogabine, an investigational anti-epileptic drug being studied for the adjunctive treatment of adults with partial onset seizures. The REMS was requested by FDA in correspondence dated 16 August 2010 and submitted to the FDA on 26 August 2010.  

The NDA was submitted to the FDA on 30 October 2009.  The companies will continue to work closely with FDA as the Agency completes its review.

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

Valeant Pharmaceuticals – Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology.  More information about Valeant can be found at www.valeant.com.

GlaxoSmithKline cautionary statement re
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant to Acquire Polish Products
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... Diagnostic Device An ophthalmic diagnostic device ... or deficiency in the human visual pathway. Ophthalmic devices ... presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and dry eyes. ...
(Date:7/25/2014)...  Semler Scientific, Inc. (Nasdaq: SMLR ... that develops patented products that assist healthcare providers ... reported financial results for the second quarter and ... "The second quarter of 2014 continued to ... , M.D., chief executive officer of Semler.  "We ...
(Date:7/25/2014)...  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... report second quarter 2014 financial results before the NASDAQ ... That same day, Arena will host a conference call ... Pacific Time). The conference call may ... 914.495.8552 for international callers. Please specify to the operator ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... , CHICAGO , Jan. 14 ... Raman detection system for ultrasensitive immunoassays.  The system provides ... of low abundance markers.  These increases in performance could ... discovery, and clinical diagnostics development. , "We find the ...
... PARSIPPANY, N.J. , Jan. 14 As ... market, the company has announced the addition of three Vice ... these positions bring a deep knowledge of the spine and ... distribution networks in their respective areas.   , Randy ...
Cached Medicine Technology:Sword Diagnostics Announces Availability of Proprietary Detection Technology for Ultrasensitive Immunoassays. 2Custom Spine Announces the Expansion of its Sales Management Team 2
(Date:7/25/2014)... UT (PRWEB) July 25, 2014 ... surfaces for the recent Nike National Invitational Tournament ... current United States Junior National Tournament (USJN) ... 25. , The flooring for these prestigious national tournaments ... than 300,000 square feet of playing surface at McCormick ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Florida Hospital and ... two not-for-profit organizations for years to come and make a ... with a $2 million dollar check to provide the support ... investment will enable MOSI to transform the IMAX Dome Theatre ... MOSI has the only IMAX Dome Theatre in the state ...
(Date:7/25/2014)... 25, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Ibuprofen and Oxcarbazepine Tablets . ... lot of Ibuprofen and one lot of Oxcarbazepine Tablets, by ... mislabeled packaging. Oxcarbazepine is used for the treatment of certain ... The reason for the recall is that Lot #142588, Expiration ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... results of which are published today in Cancer , ... 55 and 74 who had an abnormal finding on a ... reduced quality of life than did those who were screened ... as a surprise to the researchers. “We expected that participants ...
(Date:7/25/2014)... July 25, 2014 This is ... state of the Galactooligosaccharides (GOS) industry in ... overview of the industry, including definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
Breaking Medicine News(10 mins):Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3
... Document Management,(Tricom), a company specializing in the electronic ... clientele, has announced the acquisition of,Pacific Data Centers, ... services to its clients so that they can ... 1967, PDC utilizes the latest technological advances and,state-of-the-art ...
... U.S. Senate to vote soon on legislation that ... Mississippi, WASHINGTON, July 9 Seniors across,Mississippi ... Medicare,Advantage program in legislation being considered in the ... million from the Medicare Advantage,program in Mississippi alone ...
... McCain Wrong on Veterans Health Care, WASHINGTON, ... Government Employees (AFGE) launched a nationwide radio ad,campaign ... health care. In addition to the radio ads, ... Affairs, launched a Web site, http://www.fundtheva.com, and ...
... Rochester Medical Center (URMC) will collaborate with the U.S. ... repository of data that will aid academic and industry ... addition to helping researchers understand many cardiac problems, the ... detect drugs that can have dangerous effects on the ...
... DALLAS, July 9 The Maltese healthcare system,will ... leaders from around the,world learn how the island ... model for the European Union to follow. Affiliated,Computer ... discuss the future,of healthcare and information technology while ...
... behavior threaten safety, quality, OAKBROOK TERRACE, Ill., July ... can test the limits of,civility in the workplace. A ... rude language and hostile behavior among health care,professionals goes ... safety and the overall quality of care., Intimidating ...
Cached Medicine News:Health News:Tricom Document Management Expands Onshore Services with Acquisition of Pacific Data Centers, Inc. 2Health News:Mississippi Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Union Representing VA Workers Launch Nationwide Radio Campaign, Web Site and Viral Videos for Full VA Funding 2Health News:URMC, FDA to collaborate on national data repository for heart research 2Health News:URMC, FDA to collaborate on national data repository for heart research 3Health News:ACS Forum to Showcase Innovative Healthcare Model for European Union 2Health News:ACS Forum to Showcase Innovative Healthcare Model for European Union 3Health News:Joint Commission Alert: Stop Bad Behavior Among Health Care Professionals 2Health News:Joint Commission Alert: Stop Bad Behavior Among Health Care Professionals 3
Stainless steel dull finish....
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
Medicine Products: